Editorial
Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer
Abstract
Within the last few years, the programmed death 1 (PD-1) and the programmed death ligand 1 (PD-L1) immune checkpoint inhibitors have dramatically changed the treatment of cancer.
